Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Research & Development (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Research & Development for 7 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 10.93% year-over-year to $10.9 million, compared with a TTM value of $60.2 million through Dec 2025, up 10.75%, and an annual FY2025 reading of $60.2 million, up 10.75% over the prior year.
  • Research & Development was $10.9 million for Q4 2025 at aTYR PHARMA, down from $22.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $22.1 million in Q3 2025 and bottomed at $4.5 million in Q1 2021.
  • Average Research & Development over 5 years is $11.1 million, with a median of $10.6 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 150.38% in 2022, then dropped 14.45% in 2023.
  • Year by year, Research & Development stood at $6.0 million in 2021, then skyrocketed by 150.38% to $14.9 million in 2022, then fell by 14.45% to $12.8 million in 2023, then decreased by 4.13% to $12.2 million in 2024, then decreased by 10.93% to $10.9 million in 2025.
  • Business Quant data shows Research & Development for ATYR at $10.9 million in Q4 2025, $22.1 million in Q3 2025, and $15.4 million in Q2 2025.